Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NY:CANF)

0.5300 -0.0400 (-7.02%)
Streaming Delayed Price Updated: 3:58 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd Sponsored ADR (Israel)

< Previous 1 2 3 4 5 6 7 Next >
Stay updated with the stocks that are on the move in today's pre-market session.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Top movers in Monday's session
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Can Fite Biofarma: Q4 Earnings Insights
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Unusual volume stocks in Thursday's session
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
From Can-Fite BioPharma Ltd.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
 
Via Benzinga
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
From Can-Fite BioPharma Ltd.
Via Business Wire
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
From Can-Fite BioPharma Ltd.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
From Can-Fite BioPharma Ltd.
Via Business Wire
CANF Stock Earnings: Can Fite Biofarma Beats EPS, Beats Revenue for Q4 2023
CANF stock results show that Can Fite Biofarma beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Can-Fite Reports 2023 Financial Results and Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.